Retatrutide research guide
Triple GIP, GLP-1 and glucagon receptor agonist under investigation
An evidence map for retatrutide covering receptor pharmacology, the published phase 2 programme, current uncertainty and identity-testing questions.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Retatrutide, also identified in the literature as LY3437943, is a synthetic peptide engineered to activate the GIP, GLP-1 and glucagon receptors. Those three targets distinguish it from single- and dual-receptor incretin compounds. A product label or chromatographic purity percentage alone cannot establish receptor activity, clinical equivalence or sterility.
02 · Evidence position
What the literature can support
Published human evidence includes sponsor-funded randomised phase 2 trials. That is stronger than cell or animal evidence, but it does not make an independently supplied research material equivalent to the investigational product used in those trials. Australian regulators identify retatrutide among peptide products that may be unapproved therapeutic goods.
03 · Study-level map
Evidence and its limits
What human evidence exists?
A 48-week phase 2 randomised trial in adults with obesity compared several retatrutide regimens with placebo and reported prespecified efficacy and safety outcomes.
Limit: A controlled trial of a sponsor-manufactured investigational medicine does not validate the identity, purity, dose accuracy or safety of a separately sourced vial.
What is the Australian context?
The TGA names retatrutide in its current warnings about unapproved peptide products and unlawful public promotion or supply.
Limit: Regulatory status can change. The ARTG and current TGA notices must be checked rather than inferred from overseas trials or online availability.
04 · Analytical context
Questions a batch record should answer
- 01Does mass spectrometry support the expected molecular identity rather than only a matching retention time?
- 02Is the reported HPLC result an area-purity measurement, and are method conditions and integration visible?
- 03Are content, sterility, endotoxin and residual-solvent results reported separately instead of being implied by a single purity figure?
05 · Boundary conditions
What this record does not establish
- The phase 2 literature cannot be extrapolated to unverified research material.
- A chromatogram does not establish clinical safety, receptor potency or dose accuracy.
- No human-use or dosage conclusion is made by this dossier.
Sources checked
- 1.Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
PubMed / New England Journal of Medicine · 2023 · Primary study
- 2.Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
Therapeutic Goods Administration · 2026 · Regulator
- 3.Concerns regarding the public health risks associated with unapproved peptide products
Therapeutic Goods Administration · 2026 · Regulator